Since PD-1 plus chemotherapy has been well studied in NSCLC, we have tried to compare the response rates of this combination with PARPi in addition to PD-1/chemotherapy, but different treatment lines lead to a limitation. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.